BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE - Generic Drug Details

« Back to Dashboard

What are the generic sources for betaxolol hydrochloride; chlorthalidone and what is the scope of patent protection?

Betaxolol hydrochloride; chlorthalidone is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

C07AB	Beta blocking agents, selective
C07A	BETA BLOCKING AGENTS
C07	BETA BLOCKING AGENTS
C	Cardiovascular system

S01ED	Beta blocking agents
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-001	Oct 30, 1992		DISCN	No	No
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-002	Oct 30, 1992		DISCN	No	No

Expired US Patents for BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-001	Oct 30, 1992
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-002	Oct 30, 1992
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-002	Oct 30, 1992
Sanofi Aventis Us	KERLEDEX	betaxolol hydrochloride; chlorthalidone	TABLET;ORAL	019807-001	Oct 30, 1992

Betaxolol Hydrochloride and Chlorthalidone Market Dynamics and Financial Trajectory

Last updated: September 2, 2026

Betaxolol hydrochloride and chlorthalidone are mature, low-cost cardiovascular medicines with limited patent-driven value. Betaxolol hydrochloride has two commercial markets: ophthalmic products for glaucoma and, historically, oral products for hypertension. Chlorthalidone is an oral thiazide-like diuretic used mainly for hypertension. Both markets are genericized, price-sensitive, and fragmented. Financial opportunity is concentrated in manufacturing efficiency, reliable supply, branded-generic positioning, combination products, and institutional contracts rather than exclusivity.

Neither drug has a meaningful current biosimilar risk because both are small-molecule products. The principal commercial risks are generic price erosion, formulary substitution, manufacturing interruptions, and declining use of older oral beta blockers in favor of newer antihypertensive regimens.

What are betaxolol hydrochloride and chlorthalidone used for?

Betaxolol hydrochloride is a selective beta-1 adrenergic receptor blocker. Its principal U.S. commercial use is ophthalmic treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Betaxolol ophthalmic solution reduces aqueous humor production and is marketed in products such as Betoptic and generic betaxolol hydrochloride ophthalmic solution.[1]

Oral betaxolol hydrochloride was developed for hypertension. Oral beta-blocker use has shifted toward agents with stronger guideline-supported roles in heart failure, ischemic heart disease, rate control, or post-myocardial-infarction treatment. That shift limits the growth potential of oral betaxolol even where products remain approved or commercially available.

Chlorthalidone is a long-acting thiazide-like diuretic used to treat hypertension and edema. It has a longer duration of action than hydrochlorothiazide and is recognized in major hypertension guidelines as an effective blood-pressure-lowering agent.[2] Its clinical profile supports continued use, but its low price constrains manufacturer revenue.

How do the two drugs compare commercially?

Attribute	Betaxolol hydrochloride	Chlorthalidone
Primary dosage forms	Ophthalmic solution; oral tablets in certain markets	Oral tablets
Main indications	Glaucoma and ocular hypertension; hypertension for oral products	Hypertension and edema
Market status	Mature generic market; ophthalmic demand is more defensible than oral demand	Mature generic market with renewed clinical interest
Main competitors	Timolol, levobunolol, carteolol, brimonidine, prostaglandin analogs	Hydrochlorothiazide, indapamide, bendroflumethiazide
Patent value	Legacy product patents largely expired	Legacy product patents expired
Biosimilar exposure	None	None
Pricing power	Low; ophthalmic formulations may retain modest differentiation	Very low for standard tablets
Growth driver	Glaucoma prevalence, supply reliability, preservative-free or differentiated formulations	Guideline adoption, hypertension prevalence, product availability
Principal risk	Substitution by prostaglandin analogs and other glaucoma therapies	Substitution by other diuretics and fixed-dose antihypertensive combinations

Betaxolol has a somewhat more defensible commercial position in ophthalmology because ophthalmic products require sterile manufacturing, validated dropper systems, preservative controls, and regulatory compliance. Chlorthalidone tablets are easier to manufacture and face lower technical barriers, increasing price competition.

When do betaxolol hydrochloride and chlorthalidone lose exclusivity?

Both drugs lost their core market exclusivity decades ago. Their active ingredients are established small molecules with long histories of clinical use. Any original compound patents and early product patents have expired.

The relevant commercial question is no longer loss of basic-molecule exclusivity. It is whether a manufacturer has a live patent covering a specific formulation, delivery device, manufacturing process, or combination product.

Betaxolol hydrochloride exclusivity

The original Betoptic product and conventional betaxolol ophthalmic formulations are long past their core patent terms. Generic ophthalmic betaxolol products have been approved in the United States, demonstrating that the market is open to abbreviated new drug application competition.[3]

Potential residual protection can arise from:

• Preservative-free formulations.
• Multidose ophthalmic containers.
• Novel stabilizers or pH systems.
• Drug-device combinations.
• Fixed-dose combinations with other glaucoma medicines.
• Manufacturing methods or particulate-control processes.

These protections generally do not restore broad exclusivity over betaxolol hydrochloride itself.

Chlorthalidone exclusivity

Chlorthalidone is an older diuretic with no commercially meaningful composition-patent barrier in the standard tablet market. Generic chlorthalidone tablets have been available for many years. The FDA has approved multiple strengths and manufacturers, including products marketed under generic labels and branded-generic names such as Thalitone.[4]

Potential patent claims would be more likely to concern:

• Modified-release tablets.
• Dose-specific formulations.
• Combination tablets.
• Manufacturing or particle-size controls.
• Improved dissolution or stability profiles.

Standard immediate-release chlorthalidone tablets remain exposed to generic competition.

What is the Orange Book status of these drugs?

The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information. For mature products such as betaxolol hydrochloride ophthalmic solution and chlorthalidone tablets, the principal Orange Book issue is product listing rather than active composition-patent protection.[3]

Orange Book issue	Betaxolol hydrochloride	Chlorthalidone
Reference-product status	Legacy ophthalmic reference products exist; oral reference-product history is older and less commercially significant	Legacy oral reference products exist
Generic availability	Yes, particularly ophthalmic solution	Yes, for standard tablets
Core patent barrier	No broad current barrier expected	No broad current barrier expected
Paragraph IV importance	Limited unless a newly listed formulation patent appears	Limited unless a newly listed formulation patent appears
Regulatory exclusivity	No current meaningful new-drug exclusivity expected for conventional products	No current meaningful new-drug exclusivity expected for conventional products

The absence of a major current patent barrier does not eliminate approval risk. Ophthalmic generics must demonstrate pharmaceutical equivalence, sterility, container-closure suitability, and quality consistency. Chlorthalidone tablet applicants face more conventional chemistry, manufacturing, and controls requirements.

Which companies compete in the betaxolol and chlorthalidone markets?

The competitive field changes by country, dosage form, and contracting channel. In the United States, generic competition typically includes large portfolio manufacturers and specialty suppliers rather than a single dominant innovator.

Betaxolol competitors

Betaxolol ophthalmic competes against:

• Timolol ophthalmic products.
• Prostaglandin analogs such as latanoprost and travoprost.
• Alpha-2 agonists such as brimonidine.
• Carbonic anhydrase inhibitors such as dorzolamide and brinzolamide.
• Fixed-dose glaucoma combinations.

Betoptic has historical brand recognition, but generic substitution and payer controls constrain its pricing. Ophthalmic beta blockers also face clinical substitution because prostaglandin analogs are commonly preferred for first-line glaucoma treatment in many prescribing settings.[5]

Chlorthalidone competitors

Chlorthalidone competes with:

• Hydrochlorothiazide.
• Indapamide.
• Bendroflumethiazide in markets where available.
• Loop diuretics for edema-related use.
• Fixed-dose combinations containing renin-angiotensin system blockers or calcium-channel blockers.

Chlorthalidone has a favorable duration-of-action profile, but prescribing volume does not automatically translate into high manufacturer revenue. Standard tablets are inexpensive, and many prescriptions are filled through low-cost generic channels.

How strong is the patent estate for betaxolol hydrochloride and chlorthalidone?

The patent estates are weak for conventional products and potentially moderate for differentiated delivery systems.

Patent category	Betaxolol hydrochloride	Chlorthalidone
Active-ingredient patent	Expired	Expired
Conventional tablet or solution patent	Expired or commercially immaterial	Expired or commercially immaterial
Formulation patent	Possible for preservative-free or specialty ophthalmic products	Possible for modified-release or combination products
Device patent	Possible for ophthalmic dispensers	Usually not material
Method-of-use patent	Limited practical value because core indications are established	Limited practical value for hypertension and edema
Manufacturing patent	Possible, but generally narrow	Possible, but generally narrow
Overall estate strength	Low for standard product; moderate only for differentiated ophthalmic technology	Low for standard tablet; potentially moderate for specialized formulations

Method-of-use patents are unlikely to create broad market control because glaucoma, hypertension, and edema are established indications. Patent value would depend on claim scope, FDA labeling, physician adoption, and the ability to block a therapeutically substitutable generic.

Are there Paragraph IV challenges or patent litigation risks?

No major current Paragraph IV campaign is generally associated with conventional betaxolol hydrochloride ophthalmic solution or standard chlorthalidone tablets. Paragraph IV risk would become commercially relevant only if a sponsor listed a later patent covering a new formulation, delivery system, or combination product in the Orange Book.[6]

The more likely litigation scenarios are narrow:

1. A branded ophthalmic product asserts formulation or device patents against a generic applicant.
2. A generic manufacturer challenges the validity or scope of a later-listed patent.
3. A supplier disputes manufacturing-process or trade-secret rights.
4. A branded-generic company seeks to protect a differentiated dosage strength or modified-release product.

There is little strategic rationale for extensive litigation over a commodity immediate-release chlorthalidone tablet unless the patent claims support a meaningful market distinction.

What generic entry risks exist?

Betaxolol hydrochloride

Generic entry risk is high for conventional ophthalmic products. The main barriers are technical rather than patent-based. Applicants must address sterility, preservative concentration, pH, osmolality, viscosity, impurities, extractables and leachables, and container performance.

Generic substitution can be slower than in tablet markets when ophthalmologists or patients are sensitive to bottle design, tolerability, or preservative exposure. That creates some commercial protection for reliable suppliers, but not durable pricing power.

Chlorthalidone

Generic entry risk is very high for standard tablets. Manufacturing is comparatively straightforward, multiple suppliers can compete, and therapeutic substitution with hydrochlorothiazide or indapamide is feasible. Supply shortages can temporarily improve pricing or contract access, but shortages do not create durable exclusivity.

The main commercial threat is not a single Paragraph IV launch. It is cumulative price erosion from several approved manufacturers.

What are the FDA regulatory and manufacturing barriers?

The FDA regulates conventional betaxolol ophthalmic products through abbreviated new drug applications when a reference product and suitable regulatory pathway exist. Ophthalmic products require tighter quality controls than ordinary oral tablets because contamination or particulate defects can cause direct ocular injury.[7]

Chlorthalidone tablets generally present lower manufacturing complexity. Key controls include:

• Assay and content uniformity.
• Dissolution.
• Impurity profile.
• Stability.
• Tablet hardness and friability.
• Accurate low-dose manufacturing.

For both products, the most important manufacturing barrier is often supply-chain execution. Active pharmaceutical ingredient qualification, batch-release consistency, facility compliance, and reliable distribution can matter more than patent ownership.

What is the financial trajectory for these drugs?

Public companies rarely report standalone revenue for betaxolol hydrochloride or chlorthalidone. Financial analysis therefore relies on product status, prescription demand, generic pricing, market share, and portfolio economics rather than audited product-level sales.

Betaxolol financial trajectory

Betaxolol revenue is likely to remain mature to declining for conventional products. The ophthalmic segment has the stronger outlook because:

• Glaucoma prevalence increases with population aging.
• Ophthalmic products require specialized manufacturing.
• Some prescribers value established formulations and reliable supply.
• Sterile-product shortages can temporarily support demand for available suppliers.

Offsetting factors include substitution by prostaglandin analogs, generic price pressure, and the limited use of beta blockers as preferred initial glaucoma therapy in many treatment pathways.

Oral betaxolol has weaker growth prospects because it competes in a crowded antihypertensive market and has no strong exclusivity-based commercial position.

Chlorthalidone financial trajectory

Chlorthalidone has stable clinical relevance but weak revenue expansion potential. Its long duration of action and guideline support can preserve prescription demand. The product remains attractive as a low-cost hypertension medicine, particularly in public and institutional formularies.

Revenue is constrained by:

• Very low generic prices.
• High therapeutic substitutability.
• Multiple manufacturers.
• Limited ability to differentiate standard tablets.
• Lack of current patent exclusivity.

A manufacturer can improve economics through shortage participation, branded-generic distribution, contract manufacturing, high service levels, or combination-product development. Organic market growth alone is unlikely to generate material revenue expansion.

What licensing deals or commercial partnerships are relevant?

There is no widely recognized, high-value current licensing transaction centered on conventional betaxolol hydrochloride or chlorthalidone. These drugs are generally commercialized through internal generic portfolios, contract manufacturing, distribution agreements, or acquisition of established product lines.

Licensing value would be more plausible for:

• Preservative-free betaxolol ophthalmic technology.
• Novel ophthalmic delivery systems.
• Fixed-dose glaucoma combinations.
• Chlorthalidone combination tablets.
• Modified-release or adherence-oriented products.
• Geographic rights in markets with limited generic supply.

A transaction involving only standard tablets or conventional ophthalmic solution would normally be valued on manufacturing cost, market share, supply reliability, and regulatory status rather than patent life.

How do betaxolol hydrochloride and chlorthalidone compare with competing drugs?

Betaxolol has more formulation complexity and potentially better margin protection than chlorthalidone, but its therapeutic position is narrower. Chlorthalidone has stronger guideline relevance in hypertension but operates in a more commoditized oral-tablet market.

Factor	Betaxolol hydrochloride	Chlorthalidone
Demand outlook	Stable to modest decline for conventional products	Stable, with guideline-supported demand
Pricing outlook	Low; specialty ophthalmic products may retain a premium	Very low
Patent upside	Specialty formulation or device only	Combination or modified-release products only
Generic launch threat	High	Very high
Supply-chain value	High because sterile ophthalmic manufacturing is specialized	Moderate
Strategic attractiveness	Niche ophthalmic portfolio asset	Volume and formulary portfolio asset
Revenue quality	Better in differentiated ophthalmic formats	Predictable but low-margin

Key Takeaways

• Betaxolol hydrochloride and chlorthalidone are mature generic cardiovascular drugs with no meaningful broad composition-patent protection.
• Betaxolol has greater commercial defensibility in ophthalmic products than in oral hypertension products.
• Chlorthalidone retains clinical relevance but has limited revenue upside because standard tablets are inexpensive and highly substitutable.
• Conventional products face high generic-entry risk and little Paragraph IV litigation exposure.
• Biosimilar competition is irrelevant because both products are small molecules.
• The most credible value-creation opportunities involve sterile manufacturing, supply reliability, preservative-free ophthalmic formulations, delivery devices, and fixed-dose combinations.
• Financial performance depends more on cost control, contracts, shortages, and portfolio scale than on patent exclusivity.
• Any investment case should treat these products as cash-flow or supply-chain assets, not as patent-protected growth products.

FAQs About Betaxolol Hydrochloride and Chlorthalidone

Is betaxolol hydrochloride still a profitable pharmaceutical product?

It can be profitable in ophthalmic portfolios when manufacturing capacity is scarce or supply reliability commands value. Conventional oral betaxolol has weaker commercial prospects because of therapeutic substitution and generic pricing.

Does chlorthalidone have active U.S. patents?

Standard chlorthalidone tablets do not have a commercially meaningful active composition-patent barrier. Later patents could apply to specialized formulations or combinations.

Can a generic manufacturer launch chlorthalidone without a Paragraph IV challenge?

Yes. If no blocking patent applies to the referenced product, an applicant may use other applicable ANDA certification pathways, including certification that no relevant patent is listed or that the patent has expired.

Are betaxolol eye drops interchangeable with timolol?

They are pharmacologically related but are not automatically interchangeable in every regulatory or clinical setting. Substitution depends on the product, jurisdiction, payer rules, physician direction, and patient response.

Which drug has better long-term commercial potential?

Betaxolol has better potential in differentiated ophthalmic delivery formats. Chlorthalidone has more durable baseline clinical demand but lower margins and greater exposure to commodity generic competition.

References

1. U.S. Food and Drug Administration. (2017). Betoptic S (betaxolol hydrochloride ophthalmic suspension) prescribing information.
2. Williams, B., Mancia, G., Spiering, W., et al. (2018). 2018 ESC/ESH guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021-3104.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, chlorthalidone products and labeling.
5. American Academy of Ophthalmology. (2020). Primary open-angle glaucoma preferred practice pattern.
6. U.S. Food and Drug Administration. (2024). Paragraph IV drug product and patent listing procedures.
7. U.S. Food and Drug Administration. (2009). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.